ISSN:
1432-0584
Keywords:
Chlorambucil
;
Alpha-2b interferon
;
Chronic lymphocytic leukemia
;
Treatment
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Eleven patients with early CLL (two in Rai's stage 0, seven in stage I, and two in stage II) received aIFN (3 MU subcutaneously three times a week for a median of 8 months; range, 4–12) after their tumor mass had been reduced with intermittent chlorambucil. Following chlorambucil/aIFN administration, a significant reduction in blood lymphocyte counts (from 25.1±12.0×109/1 to 6.3±5.32×109/1;p〈0.001) and in CD 19-positive cells (from 21.0±12.0×109/1 to 3.8±2.3×109/1;p〈 0.001) was observed. Three of seven patients with stage-I and one of two with stage-II disease moved to stage 0, and a complete response (CR) was observed in two patients with stage-I at diagnosis. Overall, there were eight patients who, after treatment, had either a CR (2 cases) or stage-0 disease (6 cases), which compares favorably with two patients with stage-0 disease before entering the study (p=0.015). In five patients (including the two who achieved a CR) aIFN further improved the disease status achieved with chlorambucil.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01714955
Permalink
